Elliot Servais to Lung Neoplasms
This is a "connection" page, showing publications Elliot Servais has written about Lung Neoplasms.
Connection Strength
5.641
-
Servais EL, Hayanga JWA, Linden P, Sood P, Raymond DP, Antonoff MB, Chudgar NP, Keshava HB, Velotta JB, Crabtree T, Jeffrey Yang CF, Raz D, Tong B, Cooke DT, Erkmen CP, Shaller B, Kent MS, McKee A, Phan CT, Daly ME, Onaitis MW, Edwards JP, Yang SC, Merritt RE, Shrager J. The Society of Thoracic Surgeons (2025) Expert Consensus Document on Interventions for Screen-Detected Lung Nodules. Ann Thorac Surg. 2026 06; 121(6):1283-1297.
Score: 0.585
-
Watkins AA, Parsons N, Shehata DG, Vigna C, Lagisetty K, Bonner S, Lopez E, Wilder FG, Stock CT, Moffatt-Bruce S, David EA, Mitchell JD, Habib RH, Servais EL. Race, Ethnicity, and Payor Status Impact the Surgical Approach and Postoperative Outcomes of Lung Cancer Among Patients Within the Society of Thoracic Surgeons General Thoracic Surgery Database. Ann Surg. 2026 Jul 01; 284(1):83-90.
Score: 0.547
-
Watkins AA, Rizvi TZ, Lopez E, Shehata D, Ssemaganda H, Lin Z, Stock CT, Moffatt-Bruce SD, Servais EL. Trends and comparative outcomes between operative approaches for segmentectomy in lung cancer. J Thorac Cardiovasc Surg. 2025 03; 169(3):745-752.e2.
Score: 0.525
-
Servais EL. Commentary: Utilization and equity in lung cancer screening: Time to abandon the 1-size-fits-all approach? J Thorac Cardiovasc Surg. 2024 07; 168(1):261-262.
Score: 0.503
-
Kader S, Watkins A, Servais EL. The oncologic efficacy of extended thoracic resections. J Surg Oncol. 2023 Feb; 127(2):288-295.
Score: 0.475
-
Servais EL, Miller DL, Thibault D, Hartwig MG, Kosinski AS, Stock CT, Price T, Quadri SM, D'Agostino RS, Burfeind WR. Conversion to Thoracotomy During Thoracoscopic vs Robotic Lobectomy: Predictors and Outcomes. Ann Thorac Surg. 2022 08; 114(2):409-417.
Score: 0.439
-
Su L, Ho H, Stock CT, Quadri SM, Williamson C, Servais EL. Surgeon Experience Is Associated With Prolonged Air Leak After Robotic-assisted Pulmonary Lobectomy. Ann Thorac Surg. 2022 08; 114(2):434-441.
Score: 0.429
-
Watkins AA, Quadri SM, Servais EL. Robotic-Assisted Complex Pulmonary Resection: Sleeve Lobectomy for Cancer. Innovations (Phila). 2021 Mar-Apr; 16(2):132-135.
Score: 0.416
-
Ho H, Williamson C, Regis SM, Stock CT, Quadri SM, McKee BJ, McKee AB, Servais EL. Surgery and invasive diagnostic procedures for benign disease are rare in a large low-dose computed tomography lung cancer screening program. J Thorac Cardiovasc Surg. 2021 Mar; 161(3):790-802.e2.
Score: 0.402
-
Servais E, Swanson SJ. Thoracoscopic Management of Pulmonary Metastases. Thorac Surg Clin. 2016 Feb; 26(1):91-7.
Score: 0.292
-
Servais EL, Colovos C, Kachala SS, Adusumilli PS. Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden. Curr Protoc Pharmacol. 2011 Sep; Chapter 14:Unit14.21.
Score: 0.215
-
Gilyard S, Ahmed O, Kim CY, Chundury A, Donnelly EF, Knavel Koepsel EM, Lin J, Makary MS, Mehta P, Monroe EJ, Scheidt MJ, Servais E, Fidelman N. ACR Appropriateness Criteria? Radiologic Management of Pulmonary Nodules and Masses: Update 2025. J Am Coll Radiol. 2026 May; 23(5):915-927.
Score: 0.147
-
Suaiti L, Sullivan TB, Rieger-Christ KM, Servais EL, Suzuki K, Burks EJ. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. Clin Lung Cancer. 2023 05; 24(3):e126-e133.
Score: 0.118
-
Yambayev I, Sullivan TB, Rieger-Christ KM, Servais EL, Stock CT, Quadri SM, Sands JM, Suzuki K, Burks EJ. Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy. Lung Cancer. 2022 09; 171:82-89.
Score: 0.114
-
Towe CW, Servais EL, Grau-Sepulveda M, Kosinski AS, Brown LM, Broderick SM, Wormuth DW, Fernandez FG, Kozower BD, Raymond DP. Impact of Chest Wall Resection on Mortality After Lung Resection for Non-Small Cell Lung?Cancer. Ann Thorac Surg. 2022 12; 114(6):2023-2031.
Score: 0.110
-
Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol. 2021 04 01; 45(4):567-576.
Score: 0.105
-
Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 05; 6(261):261ra151.
Score: 0.067
-
Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014 Feb 15; 20(4):1020-8.
Score: 0.063
-
Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009 Jan; 137(1):13-9.
Score: 0.045
-
Kachala SS, Servais EL, Park BJ, Rusch VW, Adusumilli PS. Therapeutic sentinel lymph node imaging. Semin Thorac Cardiovasc Surg. 2009; 21(4):327-38.
Score: 0.045